

Efficacy of the treatment with a COX-2 specific inhibitor celecoxib in osteoarthritic patients

Submission date 06/07/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 08/07/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 02/10/2008	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Javier Santillana

Contact details
Orthopaedic Department
Hospital de Tortosa Virgen de la Cinta
Esplanetes 47
Tortosa - Tarragona
Spain
43500
+34 977519133
jsanmher@eresmas.com

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title

Acronym

COXOA

Study objectives

Our hypothesis is that celecoxib could have a specific antiinflammatory profile to that of a classic antiinflammatory treatment on patients with knee osteoarthritis (OA).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Advanced osteoarthritis

Interventions

Comparison of celecoxib treatment versus aceclofenac treatment

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Celecoxib and aceclofenac

Primary outcome(s)

Synovial inflammation markers on the synovial membrane of osteoarthritis patients

Key secondary outcome(s))

Effect on Western Ontario McMaster Universities Osteoarthritis (WOMAC) index

Completion date

12/02/2003

Eligibility**Key inclusion criteria**

Patients with clinical and radiological evidence of knee OA who met the American Rheumatism Association criteria for functional classes III or IV, who were scheduled for total knee replacement and who accepted to be treated with an antiinflammatory drug.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Pregnancy, gastrointestinal pathology, kidney or hepatic insufficiency, diabetes, cardiovascular disease, oncologic patients.

Date of first enrolment

12/02/2002

Date of final enrolment

12/02/2003

Locations**Countries of recruitment**

Spain

Study participating centre**Orthopaedic Department**

Tortosa - Tarragona

Spain

43500

Sponsor information**Organisation**

Hospital de Tortosa Virgen de la Cinta (Spain)

ROR

<https://ror.org/046sqxa62>

Funder(s)

Funder type

Industry

Funder Name

Mapfre Medicina Foundation (grant 2003), Spanish Ministry of Education (SAF 08/0379), Fondo de Investigaciones Sanitarias (CP03/00011), Pfizer Spain

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2008		Yes	No